New Delhi, Aug. 6 -- Biocon expects to deliver a stronger performance as FY27 progresses, with growth momentum set to accelerate during the year and a meaningful pickup in the second half for its biosimilars business, according to the company's management commentary in its Q1 FY27 investor presentation released on Thursday. The company also said it does not expect any material increase in competitive intensity in its generics business.

The investor presentation said Biocon had started FY27 on a steady footing and was well positioned to deliver stronger performance, supported by recent product launches, expanded manufacturing capacity and continued momentum in its biosimilars business. It added that recent launches and market access progr...